Calciphylaxis Market

Market Overview:

The 7 major calciphylaxis markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.6 Billion by 2034, exhibiting a growth rate (CAGR) of 7.37% during 2024-2034.

The calciphylaxis market has been comprehensively analyzed in IMARC's new report titled "Calciphylaxis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare condition that can cause tissue death due to calcium buildup in the small blood vessels. It primarily affects people with end-stage renal disease or kidney disorders but can also occur in individuals with normal kidney function. The illness typically manifests as painful skin lesions or wounds, which can progress to necrosis or gangrene if left untreated. Various other symptoms of calciphylaxis may include fever, malaise, muscle or joint pain, etc. Diagnosing the ailment can be challenging, as the indications are non-specific and resemble other skin conditions. To diagnose the disorder, a physician will typically perform a physical examination and order laboratory tests to examine the levels of calcium, phosphate, and parathyroid hormone in the blood. Several imaging studies, such as Doppler ultrasound and computed tomography (CT) scans, are also used to evaluate the extent of the disease and assess blood flow to the affected areas. Additionally, a skin biopsy may be necessary to confirm the diagnosis by examining the tissue for evidence of calcification and tissue damage.

The increasing cases of abnormal calcium and phosphate metabolism, which can lead to the deposition of calcium in blood vessels, are primarily driving the calciphylaxis market. In addition to this, the rising incidence of several associated risk factors, such as hyperthyroidism, vitamin D deficiency, obesity, use of calcium-containing phosphate binders, etc., is also propelling the market growth. Furthermore, the inflating adoption of effective medications, including sodium thiosulfate, bisphosphonates, cinacalcet, etc., for reducing the levels of calcium in the blood and preventing the formation of blood clots is acting as another significant growth-inducing factor. Apart from this, the escalating application of hyperbaric oxygen therapy, which involves breathing oxygen in a pressurized chamber to improve blood flow to the affected areas and promote wound healing, is also creating a positive outlook for the market. Moreover, the emerging popularity of advanced wound care techniques, such as negative pressure wound therapy and advanced dressings, since they can stimulate the growth of healthy tissues and reduce the risk of infection in individuals with large or deep wounds, is expected to drive the calciphylaxis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the calciphylaxis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for calciphylaxis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the calciphylaxis market in any manner.

Key Highlights:

• Calciphylaxis most commonly affects people with end-stage renal disease (ESKD) who are on dialysis.
• The incidence among patients on hemodialysis varies globally, ranging from 0.35% in the United States to less than 0.03% in Japan.
• Patients with calciphylaxis are diagnosed at a median age of 60 years, with women accounting for 60-70% of the total.
• This condition has a 55% one-year death rate.

Drugs:

SNF472 is a new small molecule that selectively and potently inhibits hydroxyapatite (HAP) crystallization, which is the final common mechanism leading to vascular calcification. SNF472 is in Phase 3 clinical research for the treatment of calciphylaxis in ESKD patients, with two different primary endpoints: wound healing and pain. The FDA and the EMA have recognized SNF472 as an orphan drug for the treatment of calciphylaxis.

Sodium thiosulfate (STS) is a known antidote for cyanide intoxication and has recently been used to treat calciphylaxis. Sodium thiosulfate is an effective antioxidant that also increases the solubility of calcium deposits.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the calciphylaxis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the calciphylaxis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current calciphylaxis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the calciphylaxis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the calciphylaxis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the calciphylaxis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of calciphylaxis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of calciphylaxis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of calciphylaxis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with calciphylaxis across the seven major markets?
• What is the size of the calciphylaxis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of calciphylaxis?
• What will be the growth rate of patients across the seven major markets?
   

Calciphylaxis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for calciphylaxis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the calciphylaxis market?
• What are the key regulatory events related to the calciphylaxis market?
• What is the structure of clinical trial landscape by status related to the calciphylaxis market?
• What is the structure of clinical trial landscape by phase related to the calciphylaxis market?
• What is the structure of clinical trial landscape by route of administration related to the calciphylaxis market?